Amylin Pharmaceuticals (AMLN)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS
*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

9360 TOWNE CENTRE DR SAN DIEGO, CA 92121

Amylin Pharmaceuticals discovers, develops and commercializes drug candidates for the treatment of diabetes, obesity and cardiovascular disease. The company has two approved products, BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection, both commercially launched in 2005.

View SEC Filings from AMLN instead.

View recent insider trading info

Funds Holding AMLN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AMLN BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

BECK TERESA

  • Director
No longer subject to file 2012-08-08 0

BEHRENS M KATHLEEN

  • Director
No longer subject to file 2012-08-08 0

GAVIN JAMES R III

  • Director
No longer subject to file 2012-08-08 0

EASTHAM KARIN

  • Director
No longer subject to file 2012-08-08 0

SKYLER JAY S

  • Director
No longer subject to file 2012-08-08 0

FOLETTA MARK G SVP, CHIEF FINANCIAL OFFICER

  • Officer
  • SVP, CHIEF FINANCIAL OFFICER
No longer subject to file 2012-08-08 0

KOLTERMAN ORVILLE G SVP, CHIEF MEDICAL OFFICER

  • Officer
  • SVP, CHIEF MEDICAL OFFICER
No longer subject to file 2012-08-08 0

ROWLAND LLOYD A VP, CHIEF COMPLIANCE OFFICER

  • Officer
No longer subject to file 2012-08-08 0

BRADBURY DANIEL PRESIDENT & CHIEF EXECUTIVE OF

  • Officer
  • PRESIDENT & CHIEF EXECUTIVE OF
No longer subject to file 2012-08-08 0

ADAMS ADRIAN

  • Director
No longer subject to file 2012-08-08 0

SULLIVAN JOSEPH P

  • Director
No longer subject to file 2012-08-08 0

LEONHARDT HARRY J SVP, LEGAL, COMPL & CORP SECTY

  • Officer
  • SVP, LEGAL, COMPL & CORP SECTY
No longer subject to file 2012-08-08 0

DENNER ALEXANDER J

  • Director
No longer subject to file 2012-08-08 0

GERGEN MARK J SVP, CORPORATE DEVELOPMENT

  • Officer
  • SVP, CORPORATE DEVELOPMENT
No longer subject to file 2012-08-08 0

MARSHALL PAUL SVP, OPERATIONS

  • Officer
No longer subject to file 2012-08-08 0

LLOYD MARCEA BLAND SVP, CHIEF ADMINISTRATIVE OFFI

  • Officer
  • SVP, CHIEF ADMINISTRATIVE OFFI
No longer subject to file 2012-08-08 0

MIHALIK VINCENT P SVP, CHIEF COMMERCIAL OFFICER

  • Officer
  • SVP, CHIEF COMMERCIAL OFFICER
No longer subject to file 2012-08-08 0

COSTA PAULO F

  • Director
No longer subject to file 2012-08-08 0

WEYER CHRISTIAN SVP, RESEARCH & DEVELOPMENT

  • Officer
  • SVP, RESEARCH & DEVELOPMENT
No longer subject to file 2012-08-08 0

CLARK PAUL N

  • Director
0 2012-04-09 0

MARCHETTI ROGER SVP, HUMAN RESOURCES & IM

  • Officer
30,728 2011-03-01 0

ALTMAN STEVEN R

  • Director
0 2010-04-05 0

EASTBOURNE CAPITAL MANAGEMENT LLC/CA

  • 10% Owner
No longer subject to file 2009-09-16 0

GREENE HOWARD E JR

  • Director
0 2009-04-03 0

GRAHAM GINGER L

  • Director
139,450 2009-04-03 0

WILSON JAMES N

  • Director
0 2009-04-03 0

COOK JOSEPH C JR

  • Director
864,601 2009-03-04 0

EBERHARD CRAIG A VP SALES

  • Officer
27,919 2009-03-04 0

BLACK BEAR OFFSHORE MASTER FUND LP

  • 10% Owner
12,116,463 2008-08-27 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments